ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
Open Access
- 11 October 2013
- journal article
- research article
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 21 (12) , 567-571
Abstract
Introduction Hypertrophic cardiomyopathy (HCM) is an autosomal dominant heart disease mostly due to mutations in genes encoding sarcomeric proteins. HCM is characterised by asymmetric hypertrophy of the left ventricle (LV) in the absence of another cardiac or systemic disease. At present it lacks specific treatment to prevent or reverse cardiac dysfunction and hypertrophy in mutation carriers and HCM patients. Previous studies have indicated that sarcomere mutations increase energetic costs of cardiac contraction and cause myocardial dysfunction and hypertrophy. By using a translational approach, we aim to determine to what extent disturbances of myocardial energy metabolism underlie disease progression in HCM. Methods Hypertrophic obstructive cardiomyopathy (HOCM) patients and aortic valve stenosis (AVS) patients will undergo a positron emission tomography (PET) with acetate and cardiovascular magnetic resonance imaging (CMR) with tissue tagging before and 4 months after myectomy surgery or aortic valve replacement + septal biopsy. Myectomy tissue or septal biopsy will be used to determine efficiency of sarcomere contraction in-vitro, and results will be compared with in-vivo cardiac performance. Healthy subjects and non-hypertrophic HCM mutation carriers will serve as a control group. Endpoints Our study will reveal whether perturbations in cardiac energetics deteriorate during disease progression in HCM and whether these changes are attributed to cardiac remodelling or the presence of a sarcomere mutation per se. In-vitro studies in hypertrophied cardiac muscle from HOCM and AVS patients will establish whether sarcomere mutations increase ATP consumption of sarcomeres in human myocardium. Our follow-up imaging study in HOCM and AVS patients will reveal whether impaired cardiac energetics are restored by cardiac surgery.Keywords
This publication has 21 references indexed in Scilit:
- Perturbed Length-Dependent Activation in Human Hypertrophic Cardiomyopathy With Missense Sarcomeric Gene MutationsCirculation Research, 2013
- Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic FunctionCirculation: Heart Failure, 2012
- Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathyJournal of Molecular and Cellular Cardiology, 2010
- Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic CardiomyopathyCirculation, 2010
- Cardiac Myosin-Binding Protein C Mutations and Hypertrophic CardiomyopathyCirculation, 2009
- The familial hypertrophic cardiomyopathy‐associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrilsThe Journal of Physiology, 2008
- Myocardial Energetics and EfficiencyCirculation, 2007
- Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic miceThe Journal of Physiology, 2001
- Altered Regulatory Properties of Human Cardiac Troponin I Mutants That Cause Hypertrophic CardiomyopathyJournal of Biological Chemistry, 2000
- Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy.Journal of Clinical Investigation, 1998